Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etofylline + theophylline
- Development stage
- Unknown
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Deriphyllin is a fixed-dose combination bronchodilator containing the xanthine derivatives etofylline and theophylline. Developed and marketed by Zydus Healthcare, it is widely used in India for the management of asthma, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The drug works primarily by non-selectively inhibiting phosphodiesterase (PDE) enzymes, which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This biochemical change results in the relaxation of bronchial smooth muscle and improved airflow to the lungs. Additionally, theophylline acts as an adenosine receptor antagonist and may enhance histone deacetylase 2 (HDAC2) activity, which can help reverse corticosteroid resistance in inflammatory lung diseases. Deriphyllin is available in various formulations, including immediate-release and sustained-release (Retard) tablets, syrups, and ampoules for injection.
- Brand names
- Deriphyllin
- Other names
- etofylline/theophylline
02
Targets
HDAC2 (Histone deacetylase 2)PDE (Phosphodiesterase family)ADOR (Adenosine receptors)
Beyond the preview
Go deeper on etofylline + theophylline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etofylline + theophylline.